Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation

J Cell Mol Med. 2018 Feb;22(2):1138-1147. doi: 10.1111/jcmm.13367. Epub 2017 Oct 24.

Abstract

Bone destructive diseases are common worldwide and are caused by dysregulation of osteoclast formation and activation. During osteoclastogenesis, reactive oxygen species (ROS) play a role in the intracellular signalling triggered by receptor activator of nuclear factor-κB ligand (RANKL) stimulation. Previously, we demonstrated that induction of antioxidant enzymes by Nrf2 activation using Nrf2-gene transfer, an ETGE-peptide or polyphenols, successfully ameliorated RANKL-dependent osteoclastogenesis. Dimethyl fumarate (DMF) has been shown to activate Nrf2 signalling and has been lately used in clinical trials for neurodegenerative diseases. In this study, we hypothesized that Nrf2 activation by DMF would inhibit osteoclastogenesis and bone destruction via attenuation of intracellular ROS signalling through antioxidant mechanisms. RAW 264.7 cells were used as osteoclast progenitor cells. We found that DMF induced Nrf2 translocation to the nucleus, augmented Nrf2 promoter-luciferase reporter activity and increased antioxidant enzyme expression. Using flow cytometry, we found that DMF attenuated RANKL-mediated intracellular ROS generation, which resulted in the inhibition of RANKL-mediated osteoclastogenesis. Local DMF injection into the calvaria of male BALB/c mice resulted in attenuated bone destruction in lipopolysaccharide-treated mice. In conclusion, we demonstrated in a preclinical setting that DMF inhibited RANKL-mediated osteoclastogenesis and bone destruction via induction of Nrf2-mediated transcription of antioxidant genes and consequent decrease in intracellular ROS levels. Our results suggest that DMF may be a promising inhibitor of bone destruction in diseases like periodontitis, rheumatoid arthritis and osteoporosis.

Keywords: HO-1; Nrf2; antioxidant response; dimethyl fumarate; osteoclast; oxidative stress; reactive oxygen species; receptor activator of nuclear factor-kB ligand.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Bone and Bones / drug effects
  • Bone and Bones / pathology
  • CD11b Antigen
  • Cell Death / drug effects
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Dimethyl Fumarate / pharmacology*
  • Genes, Reporter
  • Lipopolysaccharides
  • Luciferases / metabolism
  • Mice
  • NF-E2-Related Factor 2 / genetics
  • NF-E2-Related Factor 2 / metabolism
  • Osteoclasts / drug effects
  • Osteoclasts / metabolism*
  • Osteogenesis / drug effects
  • Promoter Regions, Genetic / genetics
  • Protein Transport / drug effects
  • RANK Ligand / pharmacology
  • RAW 264.7 Cells
  • Reactive Oxygen Species / metabolism*
  • Signal Transduction* / drug effects

Substances

  • Antioxidants
  • CD11b Antigen
  • Lipopolysaccharides
  • NF-E2-Related Factor 2
  • RANK Ligand
  • Reactive Oxygen Species
  • Luciferases
  • Dimethyl Fumarate